aa 2 212 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
aa 2 212
Aa 2 212, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+bcl+2+protein/Recombinant+Human+Bcl-xL+(minus+C-Terminus)+Protein%2C+CF/pmc13046825-412-21-26
Average 94 stars, based on 5 article reviews
Aa 2 212, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+bcl+2+protein/Recombinant+Human+Bcl-xL+(minus+C-Terminus)+Protein%2C+CF/pmc13046825-412-21-26
Average 94 stars, based on 5 article reviews
aa 2 212 - by Bioz Stars,
2026-10
94/100 stars
Images
Related Articles
Labeling:Article Title: Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression. Article Snippet: .. Briefly, EBV LCLs were labeled using a CellTrace violet cell proliferation kit (C34557, Thermo Fisher Scientific, Inc.) and co-cultured with each type of T cell at a T cell:EBV LCL ratio of 5:1 for 4 h in the presence of anti-CD178 (FasL) antibody (FasL blocker; unconjugated; 10 μg/mL; 556371, BD Biosciences; Supplementary Table 2), anti-CD253 (TRAIL) antibody (TRAIL blocker; unconjugated; 10 μg/mL; 550912, BD Biosciences; Supplementary Table 2), concanamycin A (CMA; perforin-1 blocker; 1 μg/ mL; C9705-25UG, Sigma-Aldrich, St. Louis, MO, USA), or Article Title: Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression Article Snippet: .. Briefly, EBV LCLs were labeled using a CellTrace violet cell proliferation kit (C34557, Thermo Fisher Scientific, Inc.) and co-cultured with each type of T cell at a T cell:EBV LCL ratio of 5:1 for 4 h in the presence of anti-CD178 (FasL) antibody (FasL blocker; unconjugated; 10 μg/mL; 556371, BD Biosciences; Supplementary Table ), anti-CD253 (TRAIL) antibody (TRAIL blocker; unconjugated; 10 μg/mL; 550912, BD Biosciences; Supplementary Table ), concanamycin A (CMA; perforin-1 blocker; 1 μg/mL; C9705-25UG, Sigma-Aldrich, St. Louis, MO, USA), or Recombinant:Article Title: Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression. Article Snippet: .. Briefly, EBV LCLs were labeled using a CellTrace violet cell proliferation kit (C34557, Thermo Fisher Scientific, Inc.) and co-cultured with each type of T cell at a T cell:EBV LCL ratio of 5:1 for 4 h in the presence of anti-CD178 (FasL) antibody (FasL blocker; unconjugated; 10 μg/mL; 556371, BD Biosciences; Supplementary Table 2), anti-CD253 (TRAIL) antibody (TRAIL blocker; unconjugated; 10 μg/mL; 550912, BD Biosciences; Supplementary Table 2), concanamycin A (CMA; perforin-1 blocker; 1 μg/ mL; C9705-25UG, Sigma-Aldrich, St. Louis, MO, USA), or Article Title: Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL. Article Snippet: Cathepsin D (CD), a ubiquitously expressed lysosomal aspartic protease, is upregulated in human breast carcinoma and many other tumor types.. CD has been repeatedly reported to act as key mediator of apoptosis induced by various chemotherapeutics.. However, there is still controversy over the role of enzymatic/proteolytic versus protein-protein interaction activities of CD in apoptotic signaling. Article Title: Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression Article Snippet: .. Briefly, EBV LCLs were labeled using a CellTrace violet cell proliferation kit (C34557, Thermo Fisher Scientific, Inc.) and co-cultured with each type of T cell at a T cell:EBV LCL ratio of 5:1 for 4 h in the presence of anti-CD178 (FasL) antibody (FasL blocker; unconjugated; 10 μg/mL; 556371, BD Biosciences; Supplementary Table ), anti-CD253 (TRAIL) antibody (TRAIL blocker; unconjugated; 10 μg/mL; 550912, BD Biosciences; Supplementary Table ), concanamycin A (CMA; perforin-1 blocker; 1 μg/mL; C9705-25UG, Sigma-Aldrich, St. Louis, MO, USA), or Article Title: A multi-scale systems pharmacology approach uncovers the anti-cancer molecular mechanism of Ixabepilone. Article Snippet: It has been realized that FDA approved drugs may have more molecular targets than is commonly thought.. Thus, to find the exact drug-target interactions (DTIs) is of great significance for exploring the new molecular mechanism of drugs.. Here, we developed a multi-scale system pharmacology (MSSP) method for the large-scale prediction of DTIs. Incubation:Article Title: Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL. Article Snippet: Cathepsin D (CD), a ubiquitously expressed lysosomal aspartic protease, is upregulated in human breast carcinoma and many other tumor types.. CD has been repeatedly reported to act as key mediator of apoptosis induced by various chemotherapeutics.. However, there is still controversy over the role of enzymatic/proteolytic versus protein-protein interaction activities of CD in apoptotic signaling. |
